share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  08/06 08:08
Moomoo AI 已提取核心訊息
On August 6, 2024, Clene Inc. announced the submission of new biomarker and clinical efficacy data for CNM-Au8 to the U.S. Food and Drug Administration (FDA) in support of its treatment for amyotrophic lateral sclerosis (ALS). The announcement was made through a press release, which is now filed as Exhibit 99.2 with the company's Current Report on Form 8-K. Additionally, Clene Inc. updated its corporate presentation on its investor relations website, which is furnished as Exhibit 99.1 in the same report. The company has indicated that future updates to the corporate presentation may be disseminated through its website without filing or furnishing a Current Report on Form 8-K to alert investors.
On August 6, 2024, Clene Inc. announced the submission of new biomarker and clinical efficacy data for CNM-Au8 to the U.S. Food and Drug Administration (FDA) in support of its treatment for amyotrophic lateral sclerosis (ALS). The announcement was made through a press release, which is now filed as Exhibit 99.2 with the company's Current Report on Form 8-K. Additionally, Clene Inc. updated its corporate presentation on its investor relations website, which is furnished as Exhibit 99.1 in the same report. The company has indicated that future updates to the corporate presentation may be disseminated through its website without filing or furnishing a Current Report on Form 8-K to alert investors.
2024年8月6日,Clene公司通過新聞發佈會宣佈向美國食品和藥物管理局提交CNm-Au8的新型生物標誌物和臨床療效數據,以支持其治療肌萎縮側索硬化症(ALS)的應用。該公告現已作爲附件99.2提交該公司的當前8-k表格。另外,Clene公司還在其投資者關係網站上更新了公司的企業介紹,作爲同一報告中的附件99.1提供。該公司已表示未來將通過其網站分發企業介紹的更新,無需提交或提供當前的8-k表格以通知投資者。
2024年8月6日,Clene公司通過新聞發佈會宣佈向美國食品和藥物管理局提交CNm-Au8的新型生物標誌物和臨床療效數據,以支持其治療肌萎縮側索硬化症(ALS)的應用。該公告現已作爲附件99.2提交該公司的當前8-k表格。另外,Clene公司還在其投資者關係網站上更新了公司的企業介紹,作爲同一報告中的附件99.1提供。該公司已表示未來將通過其網站分發企業介紹的更新,無需提交或提供當前的8-k表格以通知投資者。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息